

# Clinical Studies Validate Cancer Gene Delivery Platform: Landmark Publication Confirms Regin-G Effectively Targets Metastatic Cancers and Improves Patient Survival

SAN MARINO, Calif., June 22 (SEND2PRESS NEWSWIRE) – Epeius Biotechnologies ([epeiusbiotech.com](http://epeiusbiotech.com)) stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Regin-G, for metastatic cancer. The landmark article (accessible online as of June 16, 2009 in Molecular Therapy, the Official Journal of The American Society of Gene Therapy, [www.nature.com/mt/](http://www.nature.com/mt/)) documents the results of two related studies using Regin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body, while sparing normal cells and healthy tissues and organs.



Send2Press® Newswire

Following the FDA's designation of Regin-G as an Orphan Drug for the treatment of soft tissue sarcoma and osteosarcoma in 2008, the results of these two independent studies represent a major step toward gaining Accelerated Approval of Regin-G for osteosarcoma in the United States.

“It took several years of painstaking safety studies, followed by gradual, progressive dose escalations, to the point where tumor control was consistently demonstrated, said Dr. Erlinda M. Gordon, Medical Director of Epeius Biotechnologies.

Yet the progressive development strategy has finally paid off with real dividends: (1) By establishing the overall safety of the tumor-targeted gene delivery platform first and foremost, (2) By establishing critical pharmacological thresholds of bioactivity and dose-dependent efficacy for a new class of biological anti-cancer agents in otherwise intractable cancers, and (3) By validating the potential of Rexin-G to control metastatic cancer with single-agent efficacy, whereas other targeted therapies must be used in combination with one or more toxic agents in order to achieve even marginal results. The dividends for the cancer patient can now be measured in terms of overall survival, which is considered to be the gold standard in terms of evaluating efficacy.

### **About Epeius Biotechnologies**

Rexin-G® is commercially available for the treatment of all solid tumors in the Republic of the Philippines, and has “fast track status” as a treatment for pancreatic cancer in the United States. Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its high-performance gene delivery systems.

To learn more about ongoing clinical trials, licensing and corporate partnering opportunities, please contact Dr. Erlinda M. Gordon at [egordon@epeiusbiotech.com](mailto:egordon@epeiusbiotech.com), or visit [www.epeiusbiotech.com](http://www.epeiusbiotech.com).

All trademarks and service marks are the property of the respective parties.

News issued by: Epeius Biotechnologies Corporation



Send2Press® Newswire

Original Image: [https://www.send2press.com/wire/images/09-0609-EpeiusBio\\_72dpi.jpg](https://www.send2press.com/wire/images/09-0609-EpeiusBio_72dpi.jpg)

# # #

Original Story ID: (5092) :: 2009-06-0622-002

Original Keywords: Rixin-G, Epeius Biotechnologies Corporation, tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers, Rixin-G as an Orphan Drug for the treatment of soft tissue sarcoma and osteosarcoma, Dr. Erlinda M. Gordon, B-NAT Epeius Biotechnologies Corporation